RxDoctor Payments Data

Melissa Carran, MD

Neurology · Camden, NJNPI 1346266939

Payments from drug & device makers

$43,555in general payments, 2019–2025

Across 256 payments — averaging $170.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$39K
  • AbbVie$979
  • SK Life Science, Inc.$613
  • UCB, Inc.$442
  • Jazz Pharmaceuticals Inc.$187
  • Sunovion Pharmaceuticals Inc.$167
  • plus $2K from 37 others

What the payments were for

  • Speaking & faculty fees$361%
  • Food & beverage$4,40498%
  • Education$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,555 in reported general payments places this provider in the 85th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$115,263
Medicare patients
533
Services billed
803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FycompaPerampanel145$180,947
XcopriCenobamate113$136,615
AptiomEslicarbazepine Acetate20$68,989
Lacosamide487$57,026
TopamaxTopiramate48$52,459
BriviactBrivaracetam41$51,413
EpidiolexCannabidiol (Cbd)20$47,003
Levetiracetam978$34,746
VimpatLacosamide25$31,260
Oxcarbazepine278$29,174
Carbamazepine ErCarbamazepine162$28,720
ValtocoDiazepam24$26,941
Divalproex Sodium ErDivalproex Sodium301$22,612
ZonisadeZonisamide17$21,814
LamictalLamotrigine22$19,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$167$180,947145 claims
SK Life Science, Inc.Xcopri$613$136,615113 claims
UCB, Inc.Briviact, Vimpat, Nayzilam$442$95,42378 claims
Sunovion Pharmaceuticals Inc.Aptiom$167$68,98920 claims
Neurelis, Inc.Valtoco$97$26,94124 claims
PfizerNurtec Odt$101$18,69017 claims
AbbVieNamzaric$979$13,11912 claims
Upsher-smith Laboratories LLCTopiramate$14$6,440395 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 521 neurology providers in New Jersey.

Other neurology in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →